Introduction
Human pluripotent stem cells, which include embryonic stem (ES) cells 1 and iPS cells 2 , have expanded the capabilities of cell culture models and their applications in tissue engineering, regenerative medicine, and disease modeling 3, 4 . The ability of human iPS cells to self-renew indefinitely and differentiate into many cell types also makes them attractive for studying the mechanisms of organ development and function. However, development of defined methods for the generation of human kidney cells from iPS cells with specificity and high efficiency has remained elusive. By considering the roles of multiple factors within the cellular microenvironment-including the extracellular matrix (ECM) and soluble signaling factors-we developed a feeder-free and a serumfree protocol for efficient derivation of kidney glomerular podocytes from both human ES and iPS cells 5, 6 . This protocol produces human iPS cell-derived podocytes with >90% efficiency, without genetic manipulations or subpopulation selection during the differentiation procedure, and the resulting cells express lineage-specific markers and exhibit morphological characteristics consistent with the mature phenotype. Additional characterization data based on a global transcriptomic analysis of the human iPS cell-derived podocytes is also presented. Finally, we describe an in vitro method for integrating the iPS cell-derived podocytes into one channel of a two-channel microfluidic Organ Chip device, along with human glomerular endothelial cells in the second channel, to recapitulate the specialized tissue-tissue interface and selective molecular filtration function of the kidney glomerulus.
Development of the protocol
There is mounting evidence that multiple factors within the cellular microenvironment can influence cell fate decisions. These include cell interactions with neighboring cells, soluble growth factors, and both mechanical and chemical interactions between cells and the ECM [7] [8] [9] [10] [11] [12] [13] [14] [15] . Our strategy was to first identify ECM molecules that could robustly support the adhesion of human iPS cells, as well as their differentiated derivatives, as they transition from the pluripotent state to the differentiated podocyte lineage. We examined the expression of cell surface integrin receptors on human iPS cells and an immortalized human podocyte cell line (PCL) (Supplementary Fig. 1 and Supplementary Methods). We found that the integrins β1 and α v β 5 were highly expressed on both human iPS cells and the PCL ( Supplementary Fig. 1b-d) . Given the importance of β1 integrins in glomerular development and podocyte function in vivo 16, 17 , we used the ECM proteins laminin-511 and laminin-511-E8 fragment for our differentiation studies, as these ligands exhibit strong binding affinity for this integrin receptor subtype 18, 19 . We confirmed that human iPS cells cultured on the laminin-coated surfaces and treated with a medium containing activin A; the small molecule CHIR99021, which activates canonical Wnt signaling 20 ; and the Rho-associated kinase (ROCK) inhibitor Y27632 (ref. 10 ) can differentiate into mesoderm cells, as indicated by the expression of HAND1, goosecoid, and brachyury ( Figs. 1-3) . By treating the mesoderm cells with an intermediate mesoderm-inducing medium containing bone morphogenetic protein 7 (BMP7) and CHIR99021 (ref. 20 ), we obtained cells that express the nephron progenitor cell markers Wilm's tumor 1 (WT1), odd-skipped related 1 (OSR1), and paired box gene 2 protein (Pax2). We optimized the timing of the intermediate mesoderm induction and found that all of the human iPS cell (PGP1, IMR-90-1, and IISH3i-CB6) and ES cell (H9) lines examined in this study express lineage-specific markers within 16 d of differentiation, and the resulting cells can be expanded in culture for 6-8 weeks or cryopreserved (Figs. 1 and 2, Boxes 1 and 2).
To induce differentiation into mature, terminally differentiated podocytes, we treated the intermediate mesoderm cells for 4-5 d with a novel medium consisting of BMP7, activin A, vascular endothelial growth factor (VEGF), retinoic acid, and CHIR99021 (refs 5, 6 ) ( Fig. 1 ). Contrary to previous speculations based on the development of kidney organoids 21, 22 , and in accordance with in vivo studies on the development of glomerular capillaries [23] [24] [25] , we found that induction of the mature differentiated podocyte phenotype does not require supplementation with fibroblast growth factors (FGFs) such as FGF2 or FGF9. By following our differentiation method (Figs. 1 and 2), we obtained cells that exhibit morphological, molecular, and functional characteristics of mature kidney glomerular podocytes 5 , including the expression of nephrin, podocin, and WT1 proteins ( Fig. 3c ) and the podocyte-lineage-specification genes SYNPO, PODXL, MAF, and EFNB2, with a corresponding decrease in the expression of the nephron progenitor genes PAX2, SALL1, and EYA1 and the pluripotency genes POU5F1, SOX2, MYC, and NANOG (Fig. 4) . The human iPS cell-derived podocytes also developed primary and secondary foot processes 5 ( Fig. 3d) , similar to those seen in functional kidney glomerular podocytes in vivo 26 . After differentiation, the iPS cell-derived podocytes can be maintained in culture for up to 4 weeks in vitro using a commercially available medium (Complete Medium Kit with CultureBoost-R, Cell Systems) (Fig. 1) .
To develop an in vitro model of the kidney glomerulus, we engineered a two-channel microfluidic Organ Chip device 27, 28 that recapitulates the tissue-tissue structure, mechanochemical properties, and functional characteristics of a small portion of the human kidney glomerular capillary wall (Figs. 5 and 6, Box 3). The microfluidic device is made from a flexible poly(dimethylsiloxane) (PDMS) elastomer and it contains two parallel microchannels (1 × 1-mm top and 1 × 0.2-mm bottom channels) separated by a porous flexible PDMS membrane (50 µm thick, with 7-µm-diameter pores with 40-µm spacing), as previously described 5 ( Fig. 5) . We culture human iPS cell-derived intermediate mesoderm cells in the top channel and differentiate them into podocytes in situ. Primary human glomerular microvascular endothelial cells are seeded on the opposite side of the same porous ECM-coated membrane in the bottom channel to recreate the podocyte-endothelial interface (Fig. 6) , in which the glomerular basement membrane normally forms in vivo, thereby mimicking the urinary and capillary compartments of a functional kidney glomerulus.
To mimic the dynamic mechanical stretching and relaxation motion observed in living glomeruli in vivo in response to the cyclic pulsations of renal blood flow 29 , we included two hollow chambers on each side of the central microfluidic channels and applied cyclic suction (1 Hz, −85 kPa) to facilitate stretch (10% strain) and relaxation of the PDMS side walls along with the attached horizontal flexible PDMS membrane with its adherent cell layers. By co-culturing human iPS cell-derived podocytes with a layer of primary human kidney glomerular endothelial cells in the microfluidic device, we developed a human kidney Glomerulus Chip that mimics the tissue-tissue interface (Fig. 5 , top right and left) and differential molecular filtration functions of the human glomerular capillary wall, as well as Adriamycin-induced podocyte injury and albuminuria in vitro 5 . Together, our protocol enables the derivation of mature terminally differentiated podocytes from human iPS cells, as well as their integration into a functional microfluidic device with an adjacent endothelium-lined vascular circuit to recreate the structure, function, and specific drug (Adriamycin) responses of the living human kidney glomerulus in vitro.
Applications
The podocyte differentiation protocol has applications in modeling the development and function of the kidney glomerulus, understanding the mechanisms of podocyte injury in glomerulopathies, and the establishment of in vitro systems for nephrotoxicity screening and drug discovery. Although recent methods in stem cell differentiation have provided insights into the development of nephron progenitor cells [30] [31] [32] [33] , the mechanisms underlying podocyte-lineage specification and maturation remain largely unknown. This approach can be used to examine the factors that determine cell fate and tissue morphogenetic decisions in terminal differentiation of the kidney glomerulus. Thus, this protocol also provides opportunities for studying both early-and late-onset kidney diseases such as congenital nephrotic syndrome (CNS) of the Finnish type and steroid-resistant nephrotic syndrome 34, 35 . Mutations in podocyte genes have been implicated in many forms of kidney diseases [36] [37] [38] , but animal models often fail to recapitulate human physiological responses 3, 39 . This method can therefore be used in combination with genome editing technologies such as CRISPR/Cas9 (ref. 40 ) to produce isogenic human iPS cell lines that differ only by specific mutations and then differentiate them into kidney podocytes to examine disease phenotype and facilitate therapeutic discovery. The microfluidic human kidney Glomerulus Chip advances the capabilities of current tissue culture methods by providing a unique platform to simultaneously investigate the roles of multiple factors on glomerular capillary wall function, including cell-cell interactions, fluid shear stress, and mechanical deformation forces in kidney development and pathophysiology. It also provides opportunities to build more complex in vitro structures of the kidney by fluidically linking the Glomerulus Chip to functional microfluidic models of other subunits of the human kidney, such as the kidney proximal tubule, which have been described previously 41, 42 , to study the filtration and reabsorption of molecules, or by interconnecting the Glomerulus Chip to other similarly vascularized Organ Chips (e.g., with lung 28, 43 , liver 3, [44] [45] [46] , gut 47 , and bone marrow 48 ) to develop a human ʻbody-on-a-chipʼ for physiologically based prediction of pharmacokinetic/pharmacodynamic parameters in vitro [49] [50] [51] . Together, this protocol may be useful for tissue engineering, 3D bioprinting of organs, and regenerative medicine [52] [53] [54] [55] . Ultimately, this approach could enable analysis of both hereditary and chronic forms of human kidney disease, as well as facilitate therapeutic development. The methods could also provide an alternative to animal models for studying the pathogenesis of human kidney disease. Because current approaches for propagating primary glomerular podocytes often lead to loss of differentiated phenotype 56, 57 , it is possible that the factors we identified for inducing mature podocyte c CRITICAL STEP Colonies with defined borders may begin to roll up at the edge. Timing depends on the cell density. 5 Add~2 mL of trypsin-neutralizing solution to each well and gently scrape the cells using a cell lifter. 6 Pipette the cell suspension several times to form a mixture of single cells and small clumps (<200 µm). 7 Transfer the cell suspension to a 15-mL conical tube and bring to volume (15 mL) with pre-warmed DMEM/F. 8 Centrifuge for 5 min at 201g at room temperature (20-23°C phenotype from human iPS cells could be used to improve cell culture methods for primary tissues isolated from human kidney. Finally, cell-based therapy for human kidney glomerular tissue has remained largely unexplored because of several factors, including the lack of functional human kidney glomerular podocytes and a method to precisely deliver these cells to injured glomerular capillaries. We hypothesize that it also may be possible to use the human iPS cell-derived podocytes as an injectable form of cell therapy for the treatment of diseases that are characterized by podocyte loss or dysfunction.
Comparison with other methods
Our differentiation protocol is specific for the derivation of only one type of human kidney cellmature podocytes-with extremely high (>90%) efficiency. Other stem cell differentiation strategies, such as those used previously to generate kidney organoids 21, 22, 32 , produce mixed populations of cells and therefore require additional optimization strategies to guide lineage specification into podocytes. This limits their application in cases in which pure populations of podocytes are desired, such as in injectable cell-based therapies, targeted drug screening, or the development of tissue-specific models of glomerular function, which we do here by using Organ Chip technology. It also remains unclear whether the podocyte-like cells produced by kidney organoid cultures can be isolated, maintained in culture, or used for applications in different experimental systems without loss of cell phenotype and functionality, as this frequently occurs in primary cultures of kidney podocytes 57, 58 . By contrast, we POU5F1  SOX2  MYC  NANOG  KLF4  PAX2  OSR1  SIX2  SALL1  EYA1  NPHS1  NPHS2  WT1  PODXL  SYNPO  MME  PTPRO  CD2AP  ACTN4  ANLN  LMX1B  MAP1LC3A  MAP1LC3B  CDH3  PDPN  VEGFA  VIM  TJP1  MAP3K8  MAP4  PPP2R4  MAP4K2  ANGPT1  EFNB2  ITGB3  KIRREL2  TRPC6  TRPC4  COL5A1  COL6A3  COL1A2  COL3A1  COL15A1  LAMA2  MXRA8  MRA5  MAF demonstrate high levels of differentiation and functionality in our model, independent of genetic manipulation or subpopulation selection, which have not been achieved previously.
Another method that has been previously used to differentiate human iPS cells into podocytes involved the formation of embryoid bodies (EBs) in serum-containing medium 59 . As with organoids, the inherent heterogeneity of EBs results in a very low (<1%) yield of podocyte-like cells with immature phenotype, which limits their utility in applications in which a specific cell type (such as neurons or podocytes) is desired. By contrast, >90% of cells produced with our method have morphological and molecular phenotypes associated with mature glomerular podocytes. In addition, the use of serum components and poorly defined animal-derived ECM such as Matrigel and Geltrex in previous reports 59, 60 makes it unclear as to which signaling components contribute specifically to the differentiation of human kidney podocytes. Our protocol uses defined soluble signaling factors and ECM proteins that bind to specific cell surface integrins and robustly support the adhesion and induction of podocyte lineage from human iPS cells. Our protocol may therefore be better suited for studying the molecular mechanisms of podocyte development and lineage specification.
We induced the differentiation of human iPS cell-derived podocytes in our microfluidic Organ Chip device, which is not possible with previously published methods. We also engineered a functional in vitro model of the human kidney glomerular capillary wall by co-culturing the iPS cell-derived podocytes with a layer of primary human glomerular endothelial cells to form a functional endothelium-lined vasculature, as required for glomerular filtration studies. Our microfluidic model of the glomerular capillary wall also recapitulates the tissue-tissue structure and partitioning of the urinary and vascular compartments of living glomeruli, and enables the filtration of molecules such as inulin from the vascular channel into the urinary space while retaining albumin in the vasculature, much as expected in a functional human kidney glomerulus. Our microfluidic human kidney Glomerulus Chip also serves as a useful platform for studying the role of mechanical forces in glomerular development, as we demonstrated by uncovering a role for mechanical strain in podocyte differentiation and differential deposition of the glomerular basement membrane (GBM) component Collagen IV by podocytes and endothelial cells 5 . This could not be accomplished using traditional cell culture models or organoids, as they lack the tissue structure and endothelium-lined vascular circuit necessary for kidney glomerular filtration studies.
Limitations
Our differentiation method worked well for all the human ES (H9) and iPS (PGP1, IISH3i-CB6, and IMR-90-1) cell lines examined in this study. Owing to intrinsic variability in human iPS and ES cell lines 61 , however, researchers may need to adjust the protocol depending on the cell line they are using. Some of the modifications may include the use of different concentrations of the signaling factors, adjusting the timing of induction for each stage of differentiation, and altering the type of cellculture substrate or ECM component. The overall timing of our protocol is adequate for the creation of the Glomerulus Chip, and given that it typically takes several months to obtain functional cell types such as motor neurons 62 and astrocytes 63 from human iPS and ES cell lines, the derivation of mature glomerular podocytes in <30 d is considered rapid. Still, a faster protocol may be desired in some
CRITICAL We previously published a detailed method for making Organ Chip microfluidic devices 27 . For this section of the protocol, we recommend that researchers refer to the published protocol for additional details and step-by-step instructions for engineering the microfluidic organ-on-a-chip device, and follow the considerations outlined below.
Assembly of microfluidic devices • Timing 4-5 d
1 Develop the mold out of ProtoTherm 12120, using stereolithography. 2 Cast the 'urinary' and 'microvascular' channels of the devices from PDMS at a 10:1 (wt/wt) ratio of base to curing agent. Degas the prepolymer mixture and then cure for 4 h to overnight at 60°C. 3 Cast the Glomerulus Chip so that it contains two fluidic channels (a 1 × 1-mm urinary channel and 1 × 0.2-mm microvascular channel), two vacuum channels parallel to the fluidic channels, and ports for all fluidic and vacuum channels. Ensure that the urinary and microvascular channels of the device are separated by a porous PDMS membrane, which can be developed by casting against a deep reactive-ion etching (DRIE)-patterned silicon wafer (50 × 50 mm) consisting of 50-μm-high and 7-μm-diameter posts spaced 40 μm apart. 4 To produce through holes in the membrane using the microengineered post array, pour 100 μL of PDMS onto the wafer and then compress a polycarbonate backing against the post array, followed by baking at 60°C for 4 h. 5 Bond the porous PDMS membrane to the top component of the device by using oxygen plasma treatment ( ? TROUBLESHOOTING 10 Prepare primary human glomerular endothelial cells as described in Reagent setup. Dissociate the cells from a T25 flask, incubate them with 2 mL of 0.05% trypsin-EDTA for 1 min at 37°C, and stop the reaction by adding 5 mL of trypsin-neutralizing solution (Reagent setup). 11 Transfer the cell suspension to a 15-mL conical tube and bring the volume to 15 mL with Complete Medium containing serum and CultureBoost-R. Centrifuge the cells for 5 min at 201g at room temperature and aspirate the supernatant. 12 Resuspend the endothelial cells in an appropriate volume of complete medium with serum and CultureBoost-R to achieve a concentration of~2 × 10 6 cells/mL. 13 Using a 100-µL pipette with a barrier tip, gently add 10 µL of the cell suspension (~2 × 10 4 cells) to the bottom (vascular) channel of the microfluidic device. We found that a cell seeding density of 2 × 10 4 to 4 × 10 4 cells per channel works well. ? TROUBLESHOOTING 14 Before incubation, fill the top (urinary) channel of the device with DMEM/F12 to minimize evaporation in the chip and prevent the laminin-coated surface in the top channel from drying out. Incubate the chips in an inverted position at 37°C and 5% CO 2 for 3 h. c CRITICAL STEP It is important that the chip be incubated in an inverted position to ensure that endothelial cells adhere to the flexible PDMS membrane separating the two channels, as this also positions the cells in a way that allows for the establishment of the endothelial-basement membrane-podocyte interface in vitro. 15 Perform visual inspection and ensure that a complete monolayer of endothelial cells is achieved before proceeding to the next step. The chip can now be used in the original orientation such that the endotheliumlined channel is at the bottom. ? TROUBLESHOOTING 16 Remove non-adherent endothelial cells by gently pipetting the medium from the bottom channel of the microfluidic device. Then add 10 µL of fresh medium to the endothelium-lined channel. ? TROUBLESHOOTING situations, and it is conceivable that the pathways targeted by the signaling factors that we have identified for lineage specification of kidney podocytes could inform future studies focused on the establishment of more rapid methods for podocyte differentiation using technologies such as transcriptional activation 64, 65 and mechanotransduction 13, 14, 66, 67 in a synergistic or independent manner.
Clinical applications of the human iPS cell-derived podocytes may also require differentiation on a larger scale. Although differentiation of human podocytes at an industrial scale was not the goal of this work, we achieved podocyte differentiation in both the microfluidic Organ Chip device (to model glomerular development and function in a multiplexed manner) and in standard tissue culture plates, which should enable podocyte differentiation at a larger scale in the future.
Our microfluidic kidney Glomerulus Chip device also has some limitations. First, the PDMS material used in the fabrication of our model may absorb small hydrophobic molecules, which could compromise their utility in measuring the toxicity and efficacy of certain drugs. However, we and others have identified elastomers 68, 69 that do not absorb small molecules and could potentially be used as alternatives to PDMS for engineering microfluidic Organ Chips. It is also possible to use analytical techniques such as mass spectrometry to examine the real dose of drugs within the microfluidic devices for more accurate detection of effective concentrations. With these PDMS drug absorption data in hand, it is then possible to carry out pharmacokinetic modeling using these types of Organ Chips 51 . The flexible PDMS membrane with engineered pores is also thicker (50 µm) than the GBM in vivo, which is usually <1 µm thick 70 , and it lacks the curvature of glomerular capillaries. These differences are primarily due to technical challenges in engineering thin sheets of PDMS with optimal structural integrity and ease of handling. Although we achieved retention of albumin in the vascular channel and excretion of inulin across the glomerular filtration barrier, the 7-µm-diameter pores of the engineered membrane are large and allow large proteins to enter the urinary channel if cells are seeded sparsely, and thus cultures must be confluent before studies can be initiated. We found that the human iPS cell-derived podocytes and primary endothelial cells used in the microfluidic device can produce GBM components, including collagen IV 5 and laminin (S.M. and D.E.I., unpublished data), which could potentially form a more physiologically relevant barrier between the two cell layers. Results of control studies also showed that acellular chips, or chips lined by endothelium alone or by irrelevant cell types such as fibroblasts and renal proximal tubule epithelial cells (all coated with similar ECM), fail to recapitulate the selective filtration of the Glomerulus Chip 5 . Thus, our results could not be explained simply by differences in diffusion coefficients alone. In the future, it might be possible to engineer the microfluidic device such that it comprises a porous membrane made with degradable ECM molecules 71 , which would allow the cells to further remodel the basement membrane it forms and produce a barrier that would more closely resemble the GBM in vivo. This could also help overcome some of the technical challenges associated with the processing of cell-lined PDMS materials for endpoint analyses by transmission electron microscopy and scanning electron microscopy, which may be necessary to visualize podocyte foot process development and interdigitating networks.
Finally, although the Glomerulus Chip recapitulates many key functions of the glomerular capillary wall, it does not mimic all the functionalities of a whole kidney glomerulus. For example, our microfluidic device contains only a subset of cells, as compared with a whole living glomerulus. The fluid flow rate (60 µL/h) and shear stresses (0.0007 and 0.017 dyn/cm 2 ) in the urinary and vascular channels, respectively, are also lower than those observed in vivo. Overcoming this problem may require the use of a large volume of medium per experiment, which may not be practical for most laboratory settings. It is also possible to modify the experimental setup to enable fluid recirculation at higher flow rates or to use pressure-driven flow of smaller volumes of cell culture medium. 
Materials

Reagent setup
Human pluripotent stem cells Before initiating differentiation, the human iPS or ES cells should be adapted to feeder-free culture systems with mTeSR medium in Matrigel-coated plates. We use human iPS and ES cells at~70% confluency (~4 d after passaging) for differentiation experiments.
Defined mTeSR medium
Combine basal medium and supplement to make a 500-mL stock. Prepare 45-mL aliquots in 50-mL conical tubes and store at −20°C for up to 6 months. Thaw the aliquots in the refrigerator overnight and use within 2 weeks.
Matrigel
It is essential that all items that come in contact with Matrigel be kept cold to prevent it from polymerizing at room temperature (20-25°C). To thaw Matrigel, place it on ice and keep it refrigerated overnight. Prepare aliquots on ice according to the dilution factor provided by the manufacturer for each lot. Store the aliquots at −20°C until ready to use and no longer than the expiration date indicated by the manufacturer.
Matrigel-coated plates
Dilute the appropriate amount of Matrigel in 25 mL of cold DMEM/F12 in a 50-mL conical tube and mix well. Add 1 mL of Matrigel to each well of a six-well plate and incubate at 37°C for 2 h or at 4°C for a minimum of 24 h. The coated plates can be used immediately or stored at 4°C for up to 2 weeks.
Laminin 511-E8-coated plates All 2D differentiation steps were carried out in 12-well plates. For each 12-well plate, dilute an appropriate amount of laminin 511-E8 in 9 mL of sterile distilled water to achieve a concentration of 5 µg/mL. Coat the plates by adding 700 µL per well and incubate for 2 h at room temperature or refrigerate at 4°C overnight. The laminin 511-E8-coated plates can be stored for up to 1 week at 4°C.
Activin A Reconstitute in sterile PBS with 0.1% (wt/vol) BSA to make a 100 µg/mL stock. Prepare working aliquots (e.g., 100 µL) and store at −20°C for up to 6 months; avoid freeze-thaw cycles.
BMP7
Reconstitute in sterile distilled water containing 0.1% (wt/vol) BSA to make a 100 µg/mL stock. Prepare working aliquots (e.g., 100 µL) and store at −20°C for up to 6 months; avoid freeze-thaw cycles.
VEGF
Reconstitute in sterile PBS with 0.1% (wt/vol) BSA to make 100 µg/mL stocks. Prepare working aliquots (e.g., 100 µL) and store at −20°C for up to 6 months; avoid freeze-thaw cycles.
CHIR99021
Prepare a 30 mM stock solution by dissolving 2 mg of CHIR99021 in 143.3 µL of sterile DMSO. Prepare working aliquots (e.g., 5 µL) and store at −20°C for up to 1 month.
Y27632
Dissolve 10 mg of Y27632 in 3.079 mL of sterile distilled water to obtain a 10 mM stock solution. Prepare working aliquots (e.g., 100 µL) and store at −20°C for up to 6 months.
All-trans retinoic acid
Prepare a 10 mM stock solution by dissolving 10 mg in 3.33 mL of sterile DMSO. Prepare working aliquots (e.g., 500 µL) and store protected from light at −20°C for up to 6 months.
Complete Medium with CultureBoost-R Prepare the stock by adding CultureBoost-R supplement to basal medium per the manufacturer's guidelines. Store at 4°C and use within 2 weeks.
Mesoderm differentiation medium
Immediately before initiating the differentiation process or dissociating cells, prepare fresh medium consisting of DMEM/12 with GlutaMax, 100 ng/mL activin A, 3 µM CHIR99021, 10 µM Y27632, and 1× B27 serum-free supplement. As an option, 1% (vol/vol) penicillin-streptomycin may be added, in which case the volume of DMEM/12 with GlutaMax should be adjusted accordingly. Prepare the medium at a volume suitable for the scale of the experiment. We typically prepare 50 mL of medium for experiments with two 12-well plates.
Intermediate mesoderm differentiation medium Prepare medium consisting of DMEM/12 with GlutaMax, 100 ng/mL BMP7, 3 µM CHIR99021, and 1× B27 serum-free supplement. An optional 1% (vol/vol) penicillin-streptomycin may be added, in which case the volume of DMEM/12 with GlutaMax should be adjusted accordingly. This medium may be prepared in a large batch (e.g., 500 mL) divided into 50-mL working aliquots, and stored at −20°C for up to 3 months. Frozen aliquots can be thawed overnight at 4°C before use.
Podocyte induction medium
Prepare induction medium, consisting of DMEM/F12 with GlutaMax supplemented with 100 ng/mL BMP7, 100 ng/mL activin A, 50 ng/mL VEGF, 3 μM CHIR99021, 1× B27 serum-free supplement, and 0.1 μM all-trans retinoic acid. An optional 1% (vol/vol) penicillin-streptomycin may be added, in which case the volume of DMEM/12 with GlutaMax should be adjusted accordingly. It is crucial that this medium be protected from light. The medium may be prepared in a large batch (e.g., 500 mL), divided into 12-mL working aliquots, and stored protected from light at −20°C for up to 3 months. Thaw frozen aliquots overnight at 4°C before use.
Trypsin-neutralizing solution
Freshly prepare a solution consisting of DMEM/F12 with GlutaMax and 10% (vol/vol) FBS. Filter the medium by using a filter system or a Steriflip filter.
Laminin 511-coated chips Dilute the laminin 511 protein in sterile PBS containing calcium and magnesium to obtain a 50 µg/ mL solution. A volume of 500 µL is sufficient for an experiment with ten microfluidic chips. Fill both channels of the microfluidic device with the freshly prepared solution and incubate the chips overnight at 37°C. ECM-coated chips should be used within 24 h. Before cell seeding, gently remove the ECM solution by pipetting and rinse the chips three times with prewarmed DMEM/F12.
Permeabilization buffer
Prepare a solution consisting of 0.125% (vol/vol) Triton X-100 in PBS. This solution can be prepared in a large batch (e.g., 500 mL) and stored at room temperature for up to 1 month.
Procedure c
CRITICAL We have optimized multiple parameters in this differentiation protocol, including the type of ECM used, soluble factors and their concentrations, timing of differentiation, and the frequency of medium change. We strongly recommend that researchers follow this protocol as described.
Maintenance of human iPS cells in feeder-free culture with mTeSR medium • Timing~7 d
c CRITICAL All iPS cell maintenance culture described here uses defined mTeSR medium and six-well tissue culture-treated plates coated with human ES cell-qualified Matrigel. For all cell lines used in this study, 1-2 min was sufficient to achieve cell dissociation.
? TROUBLESHOOTING 6 Add 3 mL of mTeSR to each well and gently scrape the cells using a cell lifter. 7 Pipette several times to obtain a cell suspension with small clumps. Add 0.5 mL of the iPS cell suspension to each well of the newly prepared Matrigel-coated six-well plates. Add an additional 2 mL of mTeSR medium to each well and shake the plates gently to distribute the cells. 8 Maintain the iPS cells at 37°C in a 5% CO 2 incubator. Replace the medium daily. 9 Passage the cells approximately every 6 d or when they reach~80% confluency.
Preparation of human iPS cells for differentiation • Timing~4 d c
CRITICAL We recommend starting all differentiation studies with iPS cell cultures that are in the mitotic phase. This is typically achieved when human iPS cells are within the first 4 d of passaging or when the cells are no more than 80% confluent. We use cells after 3-4 d of passaging and at a maximum of~70% confluence.
Perform visual inspection of the iPS cells colonies that have been cultured for 3-4 d after passaging
and are~70% confluent to make sure that there are no spontaneously differentiated cells. If necessary, remove differentiated cells by scraping or aspiration under sterile conditions. Add 2 mL of mTeSR medium to each well and place the cells at 37°C in a 5% CO 2 incubator until needed for mesoderm differentiation as described in Step 13.
Differentiation of human iPS cells into mesoderm cells • Timing 2 d
11 Prepare laminin 511-E8-coated plates (Reagent setup). 12 Prepare the mesoderm induction medium (Reagent setup). 13 Working in a biosafety cabinet and under sterile conditions, aspirate mTeSR medium from iPS cells cultured on Matrigel-coated plates (Step 10). Rinse the cells three times with prewarmed DMEM/F12. 14 Dissociate the iPS cells by incubating them with enzyme-free cell dissociation buffer (1 mL per well of a six-well plate) for~10 min in a 37°C incubator. Timing may depend on the density of the iPS cell colonies, as well as on the cell line. Visually inspect the iPS cells to ensure that the colonies are dissociated. It is normal to have some floating cells. 15 Using a cell lifter, gently scrape the cells and pipette the cell suspension into a conical tube.
For example, transfer up to two wells of dissociated iPS cells to a 15-mL conical tube. Pipette the cells few times to individualize the iPS cells. Bring the conical tube up to a 15-mL volume by using prewarmed DMEM/F12 and centrifuge the cells for 5 min at 290g at room temperature (20-23°C) . Remove the supernatant and resuspend the cells again in prewarmed DMEM/F12 for another round of centrifugation under the same conditions. The second round of centrifugation should minimize the retention of residual components such as Matrigel (from scraping the plates) and cell dissociation reagent in the final cell suspension for seeding in the plates coated with the defined laminin 511-E8. 16 Aspirate the supernatant and resuspend the cells first in a small volume (~1 mL) of mesoderm induction medium. Using a hemocytometer or other cell-counting device, determine the number of cells and add an appropriate volume of mesoderm induction medium to achieve a concentration of 10 × 10 4 cells per mL. 17 Aspirate the ECM solution from the newly prepared laminin 511-E8-coated plates (Step 11) and rinse the plates twice with DMEM/F12. Remove residual DMEM/F12 before adding the cell suspension in the following step. 18 Mix the iPS cell suspension well by pipetting a few times and then transfer 1 mL of the cell suspension to each well of a 12-well plate coated with laminin 511-E8. Shake the plate gently to distribute the cells and incubate at 37°C in a 5% CO 2 incubator. c CRITICAL STEP It is important that the medium be refreshed daily, as the cells are metabolically active and quickly deplete the growth factors and supplements. If the medium becomes too acidic (typically yellow in appearance), increase the volume of the medium (e.g., to 1.3 mL per well of a 12-well plate). Some researchers may wish to experiment with growth factors that are packaged for controlled release into the cell culture medium, but this will need to be tested for feasibility and effectiveness in the differentiation of each iPS cell line. (ii) Prepare podocyte induction medium (Reagent setup) at a volume suitable for the scale of your experiment. A total of 50 mL of the podocyte induction medium is sufficient for an experiment using a 12-well plate. c CRITICAL STEP It is important to protect this medium from light. The podocyte induction medium container can be wrapped with foil during prewarming, handling, and storage. (iii) Prepare 25 mL of trypsin-neutralizing solution (Reagent setup) for each 12-well plate.
(iv) Rinse the intermediate mesoderm cells three times with prewarmed DMEM/F12. (v) Dissociate the cells by incubating them with 0.05% trypsin-EDTA at 0.5 mL per well of a 12-well plate for~3 min at 37°C. Timing will depend on cell density and the human iPS cell line used. We typically passage the intermediate mesoderm cells when they are~100% confluent, and 3 min of incubation with trypsin was sufficient for dissociation of cells derived from all the human iPS and ES cell lines used in the previous study. (vi) Pipette the cells several times, using a pipette with a P1000 barrier tip. Perform a visual check to ensure that the cells are properly dissociated into either individual cells or small clumps. Avoid clumps that are larger than 200 µm in size, as they may not spread out well or could fail to exhibit differentiated podocyte morphology at the end of the induction time line (Fig. 2, . Cells may also be analyzed by flow cytometry 5 , which will also enable the evaluation of differentiation efficiency (Fig. 3) . c CRITICAL STEP For flow cytometry analysis, we recommend that the differentiated podocytes be characterized for dual expression of lineage-identification markers such as nephrin and podocin. Because the expression of associated markers of podocytes such as WT1 is not restricted to kidney podocytes, we recommend that the expression of this marker be examined in combination with that of either nephrin or podocin, as we previously described (xviii) Incubate the cells with a blocking solution consisting of 2% (wt/vol) BSA and 0.125% (wt/vol) Triton X-100 in PBS for 2 h at room temperature. (xix) Incubate the cells with primary antibodies in permeabilization buffer overnight at 4°C. For example, the top channel containing the human iPS cell-derived podocyte layer can be immunostained for nephrin or podocin, and the bottom channel containing the endothelial cells can be immunostained for VE-cadherin. c CRITICAL STEP As WT1 alone is not a definitive marker for kidney podocytes, we recommend immunostaining for multiple lineage-identification markers, such as nephrin and podocin, at the end of the podocyte differentiation protocol. 
Troubleshooting
Troubleshooting advice can be found in Table 1 .
Timing
Steps 1-9, maintenance of human iPS cells in feeder-free culture with mTeSR medium:~7 d
Step Step 25A(i-xx), derivation of mature kidney podocytes using laminin-coated tissue culture plates: 4-5 d
Step 25B(i-xxviii), differentiation of human iPS cell-derived podocytes in microfluidic devices, and the establishment and analysis of the Glomerulus Chip:~12 d Box 1, passaging of human iPS cell-derived intermediate mesoderm cells:~3 h Fluid in microfluidic channels dries up during ECM coating or cell seeding Check that appropriate temperature and humidity levels are maintained in the incubator. In addition, add water to sterile conical tube caps and place them in the Petri dish containing the microfluidic chips 25B(xii)
Temperature rises in the incubator while the pump is running Some fluidic pumps get very hot during operation. We have previously observed this problem while using syringe pumps for perfusion but have not experienced a similar issue with the peristaltic pump listed in the 'Equipment' section. We recommend that the incubator's temperature be monitored before and during operation of the pump 25B(xiii) Medium flows too quickly or slowly during perfusion Calibrate the peristaltic pump and check that the 2-stop tubing and cartridge are properly secured to the pump 25B(vi) and Box 3, steps 9 and 13
Trapped air bubbles are seen during ECM coating or cell seeding in the microfluidic chips Remove the ECM solution or cell suspension by pipetting and repeat the step slowly Box 3, step 9
Hydrophobic microfluidic chip Check that the plasma treatment machine is working properly 25B(vii) and Box 3, step 16
Cells fail to attach to the ECM-functionalized chip Either start the experiment with new chips or decellularize the used chip, followed by baking at 60°C for a minimum of 4 h, and then repeat the plasma activation step. In addition, check that the plasma machine is working properly 25B(xii) Medium reservoirs are not flowing equally Inspect the chips for ruptured membranes or blockage by debris. In addition, check that the 2-stop tubing on the pump and the cartridge is properly secured to the pump 25B (vi) (Figs. 1 and 2) . The mesoderm cells express the lineage markers HAND1, goosecoid, and brachyury (Fig. 3a) . The intermediate mesoderm cells express WT1 and Pax2 (Fig. 3b) , and although they transiently express OSR1 within the first 10 d of differentiation, they should not express the mesodermal marker brachyury after 16 d of differentiation 5 . Subsequent treatment of the intermediate mesoderm cells with the podocyte induction medium described in this report enables the derivation of kidney podocytes with morphological and molecular characteristics of the mature phenotype (Fig. 3c-e) .
Whole-transcriptome analysis (Supplementary Methods) revealed that the human iPS cell-derived podocytes are more similar to an established human PCL than the undifferentiated iPS cells based on a global gene expression profile ( Fig. 4a and Supplementary Fig. 2 ). Consistent with the functional characterization 5 , the human iPS cell-derived podocytes express higher levels of genes that have critical roles in the lineage specification and functional maturation of kidney glomerular podocytes in vivo, which include SYNPO, MAF, PODXL, MAP1LC3B and EFNB2 (which encode synapopodin, Maf, podocalyxin, microtubule associated protein 1, and ephrin B2, respectively) (Fig. 4b) . Given the substantial contribution of podocytes to the GBM composition in vivo [74] [75] [76] , it is intriguing that the human iPS cell-derived podocytes also exhibit significant (adjusted P value <0.001 and false discovery rate <0.05) upregulation of several genes, including COL5A1, COL6A3, LAMA2, MXRA8, MRA5, and CHPF, that are involved in the synthesis and remodeling of the GBM. This differentiation protocol might therefore provide an opportunity to model human kidney development and disease pathogenesis in vitro.
To develop an in vitro model of the glomerular capillary wall using microfluidic Organ Chip technology, we recommend that researchers differentiate the podocytes in situ, rather than terminally differentiating the cells on traditional tissue culture plates and then transferring them to the microfluidic cell culture system. In addition to enhancing the differentiation phenotype (when fluid flow and mechanical strain are applied), this also prevents damage to the podocytes that typically results from treatment with cell dissociation enzymes such as trypsin. Differentiation of the human iPS cell-derived podocytes and co-culture with primary human glomerular endothelial cells on opposing sides of the flexible PDMS membrane in the microfluidic device (Fig. 5, second row) enable the establishment of a human kidney Glomerulus Chip (Fig. 3a,b) , in which the interfaced podocyte and endothelial cell layers express nephrin and VE-cadherin, respectively (Fig. 6c) . Together, this protocol provides a chemically defined method for the derivation of mature podocytes that recapitulate the structure and function of the kidney glomerular capillary wall in a microfluidic Organ Chip. Depending on the goal of the experiment, the cell-lined microfluidic device can be maintained in culture for at least a month. This microfluidic model can be used to study the selective molecular filtration function, as well as drug toxicities of the human kidney glomerulus, in vitro 5 . This protocol may also be useful for 3D bioprinting of organs, tissue engineering, and regenerative medicine in the future.
